Literature DB >> 2510061

Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.

V De Bock1, D Verbeelen, V Maes, J Sennesael.   

Abstract

Vancomycin is widely used for the treatment of infections with Gram-positive bacteria in patients with end-stage renal disease. The concentration of vancomycin in serum, in ultrafiltrate, and in dialysate was measured during nine haemofiltration and seven haemodialysis procedures with high-permeability membranes. The t1/2 of vancomycin was 101 +/- 19 h in the interdialytic and interhaemofiltration period. There was no significant difference between the haemodialysis clearance (55.2 +/- 18.5 ml/min) and the haemofiltration clearance (66.8 +/- 13.6 ml/min). The redistribution phenomenon was about 25% in the post haemofiltration period and only 10% in the post haemodialysis period. Approximately 270 mg of vancomycin was recovered in dialysate or ultrafiltrate. With high-permeability membranes more commonly used in patients with end-stage renal disease, continuous monitoring of vancomycin therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510061

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  Lesson of the month 2: An easily missed cause of confusion.

Authors:  Ben Oliveira; Sangita Chaterjee; Aine Burns
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

2.  Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.

Authors:  J Zoer; A M Schrander-van der Meer; W T van Dorp
Journal:  Pharm World Sci       Date:  1997-08

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.

Authors:  J Böhler; P Reetze-Bonorden; E Keller; A Kramer; P J Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 6.  Glycopeptides and nephrotoxicity.

Authors:  A W Chow; R M Azar
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

7.  Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.

Authors:  J M Kinowski; J E de la Coussaye; F Bressolle; D Fabre; G Saissi; O Bouvet; M Galtier; J J Eledjam
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 8.  Critical care in uraemic children.

Authors:  J U Leititis; M Brandis
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

9.  The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril.

Authors:  A Guérin; G Resplandy; S Marchais; F Taillard; G London
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear).

Authors:  Hussain Allawati; Linda Dallas; Sreejith Nair; Janine Palmer; Shaiju Thaikandy; Colin Hutchison
Journal:  Toxins (Basel)       Date:  2020-05-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.